• Publications
  • Influence
Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients
Atorvastatin is increasingly used as a cholesterol‐lowering agent in solid organ transplant recipients receiving cyclosporine A (CsA). However, the potential bilateral pharmacokinetic interactionExpand
  • 125
  • 10
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
PurposeTacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by CYP3A4 and CYP3A5. Several studies have demonstrated an association between the CYP3A5 genotype and Tac dose requirements.Expand
  • 89
  • 8
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
BACKGROUND The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors andExpand
  • 51
  • 5
  • PDF
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International AssociationExpand
  • 65
  • 4
Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients
Mycophenolic acid, the active moiety of mycophenolate mofetil, inhibits the enzyme inosine monophosphate dehydrogenase. The main metabolite, mycophenolic acid glucuronide, has no immunosuppressiveExpand
  • 34
  • 3
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts.
Monitoring of azathioprine (AZA) therapy by the measurement of 6-thioguanine nucleotides (6-TGN) concentrations in red blood cells (RBC) may improve safety and ensure optimal immunosuppressiveExpand
  • 46
  • 2
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Abstract: In association with therapeutic drug monitoring of immunosuppressive drugs, pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or, more interestingly toExpand
  • 42
  • 2
Calcineurin Inhibitor‐Free Immunosuppression in Renal Allograft Recipients with Thrombotic Microangiopathy/Hemolytic Uremic Syndrome
Thrombotic microangiopathy (TMA) and hemolytic uremic syndrome (HUS) represent serious threats to kidney allograft recipients.
  • 53
  • 2
Importance of hematocrit for a tacrolimus target concentration strategy
PurposeTo identify patient characteristics that influence tacrolimus individual dose requirement in kidney transplant recipients.MethodsData on forty-four 12-h pharmacokinetic profiles from 29Expand
  • 58
  • 2
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Objective. Mycophenolic acid (MPA) exerts its immunosuppression by inhibiting inosine 5′‐monophosphate dehydrogenase (IMPDH), depleting activated lymphocytes of guanine nucleotides and retardingExpand
  • 33
  • 2